ABSTRACT
BACKGROUND: Vitreous floaters are a common ocular condition that affects individuals of all ages. Although vitreous floaters are typically benign, they can significantly impair visual acuity and quality of life. Laser vitreolysis, which uses an Nd: YAG laser to vaporize collagenous vitreous opacities, is increasingly being used as a treatment option. However, there is currently a lack of evidence regarding its efficacy and the appropriate timing of its application. This study aims to evaluate the efficacy and safety of early intervention with YAG laser vitreolysis in treating symptomatic vitreous floaters. METHODS: The present study is a randomized, controlled, double-blind clinical trial. A total of 70 participants with symptomatic floaters for 1 month were prospectively recruited. These participants will be randomly assigned to two groups, with 35 individuals in each group: the early treatment group and the delayed treatment group. Participants assigned to the early treatment group will undergo YAG laser vitreolysis immediately, followed by a sham laser treatment 3 months later. On the other hand, participants assigned to the delayed treatment group will receive a sham laser treatment and then undergo YAG laser vitreolysis 3 months later. The follow-up time points will be 1, 3, 6, and 12 months from randomization. Primary outcomes will be participants' self-reported improvement in visual disturbance on a scale of 1 to 10 and their scores on the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). Secondary outcomes will be an objective evaluation of the effectiveness of the treatment in reducing vitreous floaters through OCT and fundus photography and tracking any adverse events related to the eyes or overall health. DISCUSSION: This clinical trial aims to evaluate the effectiveness of YAG laser vitreolysis in treating symptomatic vitreous floaters and assess the safety of performing early intervention with YAG laser vitreolysis. TRIAL REGISTRATION: ClinicalTrials.gov NCT05800353 . Registered on 10 March 2023.
Subject(s)
Laser Therapy , Lasers, Solid-State , Vision Disorders , Humans , Vitreous Body/surgery , Vitrectomy/methods , Lasers, Solid-State/adverse effects , Quality of Life , Laser Therapy/methods , Randomized Controlled Trials as TopicABSTRACT
Objective To investigate the efficacy of ganciclovir in viral keratitis and its influence on serum related indicators.Methods Patients with viral keratitis from May 2012 to December 2013 in our hospital were randomly divided into control and observation groups, each group had 62 cases.Patients in control group were treated with acyclovir eye drops, and those in observation group were treated with ganci-clovir ophthalmic gel.The difference in efficacy of two groups was compared.The levels of serum inflamma-tory cytokines of interleukin-2 (IL-2), IL-4, IL-6, IL-8, tumor necrosis factor-α(TNF-α), and interferon-γ( IFN-γ) of two groups before and after treatment were compared, the serum levels of nitric oxide ( NO) , super oxide dismutase (SOD), malondialdehyde (MDA), C3, and C-reactive protein (CRP) were been compared.Results The pain relief time and corneal healing time of observation group [(3.41 ±0.89)d and (4.02 ±1.11)d] were all shorter than control group [(4.52 ±1.21)d and (6.30 ±1.45)d].The cure rate and total effective rate of observation group were 58.06%and 90.32%, respectively.It was sig-nificantly higher than control group ( P <0.05).After 3 and 7 days of treatment, the serum levels of IL-4, IL-6, and IL-8 were lower than control group, and IL-2, and IFN-γwere higher than control group (33.87%and 82.26%) ( P <0.05).After 3 and 7 days of treatment, the serum levels of NO and MDA were lower than control group, and SOD, C3, and CRP were higher than control group ( P <0.05).Con-clusions Ganciclovir has a better efficacy than acyclovir for viral keratitis, and can effectively adjust the serum levels of related indicators.
ABSTRACT
The paper analyzes employment and psychological status among graduates, points out the advantages that college and uni-versity libraries carry out service of employment guidance, discusses safeguard measures and proposes main contents and methods of it.
ABSTRACT
Objective:To evaluate the biological characters of C57-TgN(HBV adr2.0)SMMU transgenic mice. Methods: Integration,expression,replication and histology change of hepatitis B virus gene in F6 transgenic mice were estimated by ge-nomic DNA PCR,Western blotting,ELISA,immunohistochemistry,serum DNA PCR,transmission electron microscopy and H-E staining. Results: Hepatitis B virus gene was integrated into F6 C57-TgN(HBV adr2. 0)SMMU transgenic mice and expressed HBsAg,HBcAg and X protein in liver tissue. HBsAg and HBeAg were expressed in serum of 19. 54% and 3. 39% F6 transgenic mice. Hepatitis B virus were replicated in serum and liver tissue of transgenic mice. Long-term integration,expression and replication of hepatitis B virus gene induced pathological lesion of transgenic mice liver and lung. Conclusion: C57-TgNCHBV adr2. 0)SMMU transgenic mice line has the biological characters including integration of hepatitis B virus gene into genomic DNA,expression and replication of hepatitis B virus gene in serum and liver, and histological change in liver and lung. It is a valuable animal system to study pathogenesis, treatment and prevention of hepatitis B virus.
ABSTRACT
Objective: To clone mouse rod opsin promoter (ROP) and establish transgenic mice harboring mouse rod opsin promoter and enhanced green fluorescent protein(mROP-EGFP) fusion gene. Methods: Mouse ROP was cloned from C57BL/6 mouse genomic DNA by polymerase chain reaction (PCR). Expression vector of mROP-EGFP fusion gene were constructed by recombination DNA technique. It was identified by restriction endonucleases digestion and confirmed by DNA sequencing. After Not I restriction endonuclease digestion, the coding elements were microinjected into male pronuclei of mice zygotes to generate transgenic mice. The pups were evaluated by PCR at genomic DNA level and mated with normal mouse. Expression of GFP in retina of transgenic mice was detected by fluorescent microscope. Results: 2. 1 kb mouse rod opsin promoter fragment was amplified from mice genome DNA. Expression vector pmROP-EGFP was constructed successfully. Following microinjection of coding sequence of pmROP-EGFP, 3 pups were verified to integrate the mROP-EGFP fusion gene in their genomic DNA by PCR assay, named C57-TgN (mROP-EGFP )SMMU21, C57-TgN (mROP-EGFP)SM-MU26 and C57-TgN(mROP-EGFP) SMMU27. They could express GFP in retina. Conclusion: 2. 1 kb mouse rod opsin promoter is cloned and expression vector pmROP-EGFP is constructed. mROP-EGFP fusion gene transgenic mice are established, which harboring mROP-EGFP gene and expressing GFP in their retina. This is valuable for studying the development of brain and retina, pathogenesis of retina disorder and retina transplanting.
